Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02253173 · ClinicalTrials.gov registry record · Phase 3

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

A Phase 3 study, sponsored by TherapeuticsMD.

Completed
Registry status
Phase 3
Development phase
764
Enrollment target

NCT02253173 is a Phase 3 study that has completed, run by TherapeuticsMD. The registered enrollment target is 764 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02253173, a Phase 3 study, has completed, sponsored by TherapeuticsMD.

COMPLETED
Registry status
Phase 3
Development phase
764 participants
Enrollment target

Study Summary

This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.

Interventions

  • DRUG Placebo
  • DRUG Estradiol

Trial Details

FieldValue
Enrollment Target 764 participants
Start Date 2014-09
Est. Completion 2015-10
Phase Phase 3

Sponsor

TherapeuticsMD

5 total trials

What the Registry Record Tells You About NCT02253173

The ClinicalTrials.gov registry entry for NCT02253173 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 764 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TherapeuticsMD, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02253173 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02253173 about?

NCT02253173 is a clinical study titled "Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women". This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.

What is the current status of trial NCT02253173?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 764 participants. The study started on 2014-09. Estimated completion is 2015-10.

What interventions are being tested in trial NCT02253173?

The interventions under investigation include: Placebo (DRUG), Estradiol (DRUG).

Who is sponsoring clinical trial NCT02253173?

This trial is sponsored by TherapeuticsMD, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.